Gerard Oghlakian, MD
Advanced Heart Failure and Transplant Cardiology · Springfield, MONPI 1679779979
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $298,969 of the $365,467 with a category attached, or 81.8%. 21 manufacturers reported payments, led by Boehringer Ingelheim at 46.6% of the total. Among advanced heart failure and transplant cardiology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 425 payments — averaging $859.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$170K
- E.r. Squibb & Sons, L.L.C.$96K
- Novartis$42K
- AstraZeneca$30K
- Lilly USA, LLC$19K
- Amgen$7K
- plus $2K from 15 others
Across 51 payments — averaging $2418.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$73K
- AstraZeneca$37K
- Novartis$12K
- Merck$2K
What the payments were for
- Consulting fees$6,1632%
- Speaking & faculty fees$298,96982%
- Travel & lodging$49,02613%
- Food & beverage$11,3103%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 137 | $170,185 |
| E.r. Squibb & Sons, L.L.C. | 98 | $96,349 |
| Novartis | 58 | $41,543 |
| AstraZeneca | 54 | $30,016 |
| Lilly USA, LLC | 21 | $18,502 |
| Amgen | 12 | $7,249 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $379 |
| Boston Scientific | 8 | $220 |
| Abbott | 6 | $169 |
| Heartflow, Inc. | 2 | $166 |
| Alnylam Pharmaceuticals Inc. | 1 | $147 |
| Abiomed | 4 | $147 |
| Pfizer | 3 | $146 |
| Philips North America LLC | 1 | $131 |
| Lantheus Medical Imaging, Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $20 |
| Bayer | 1 | $17 |
| Merck | 1 | $16 |
| Shockwave Medical, Inc | 1 | $15 |
| Amicus Therapeutics, Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$187,092
- CAMZYOS$80,848
- ENTRESTO$39,336
- FARXIGA$28,942
- Repatha$7,000
- LEQVIO$1,363
- AMVUTTRA$147
- FFRct$142
- (AO0) IGT Devices Intracardiac$131
- AVVIGO Guidance System$130
How this compares
$365,467 in reported general payments places this provider in the 95th percentile of 26 advanced heart failure and transplant cardiology providers in Missouri.
See all advanced heart failure and transplant cardiology providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 427 | $402,932 |
| EntrestoSacubitril/Valsartan | 287 | $338,910 |
| JardianceEmpagliflozin | 219 | $236,863 |
| CamzyosMavacamten | 19 | $152,685 |
| FarxigaDapagliflozin Propanediol | 109 | $108,295 |
| XareltoRivaroxaban | 86 | $76,931 |
| Repatha SureclickEvolocumab | 44 | $52,752 |
| BrilintaTicagrelor | 17 | $10,615 |
| Metoprolol Succinate | 413 | $3,613 |
| Atorvastatin Calcium | 432 | $2,969 |
| Flecainide Acetate | 100 | $2,560 |
| Potassium Chloride | 109 | $1,857 |
| Bumetanide | 55 | $1,707 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 153 | $1,447 |
| Ezetimibe | 87 | $1,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $146 | $402,932427 claims |
| NovartisEntresto | $41,543 | $338,910287 claims |
| Boehringer IngelheimJardiance | $170,185 | $236,863219 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $96,349 | $152,68519 claims |
| AstraZenecaFarxiga, Brilinta | $30,016 | $118,909126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 26 advanced heart failure and transplant cardiology providers in Missouri.
Other advanced heart failure and transplant cardiology in Springfield
- Andrew SauerLees Summit$411K
- Brett SperryKansas City$314K
- Shane LarueHannibal$41K
- Gregory EwaldSaint Louis$35K
- Sumanth PrabhuSaint Louis$35K
- Nancy SweitzerSaint Louis$32K
- Michael NassifKansas City$32K
- Justin HartupeeSaint Louis$30K
- Timothy FendlerLees Summit$15K
- Kory LavineSaint Louis$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.